CoChat
Sign Up
Cited by 73Neuroendocrine regulation and behaviorAutism Spectrum Disorder ResearchGenetics and Neurodevelopmental Disorders

Refining oxytocin therapy for autism: context is key

Open access
Ford, Charles L., Young, Larry J.·2022·Nature Reviews Neurology
DOI 10.1038/s41582-021-00602-9PMC PMC8816821
Open this paper in CoChat — free account

Abstract

A recent clinical trial found no effect of chronic intranasal oxytocin on social behaviour in children with autism spectrum disorders. The result is not surprising, as oxytocin facilitates social learning but does not directly cause prosocial behaviour. In future trials, oxytocin should be paired with behavioural therapy to enhance learning and improve social behaviour.

AI snapshot

Written from the paper’s full text.

TL;DR

A recent phase II trial found no effect of chronic intranasal oxytocin on social behaviour in children and adolescents with autism spectrum disorders (ASD). The authors argue this is unsurprising because oxytocin enhances social salience and learning rather than directly causing prosocial behaviour, so future trials should pair oxytocin with behavioural therapy and appropriate social context.

Key findings

  • In the Sikich et al. trial discussed, 290 participants aged 3–17 years with ASD were enrolled across seven academic sites; 277 provided data. They received twice-daily target doses of 24–40 international units (IU) of intranasal oxytocin or placebo for up to 24 weeks, and oxytocin had no effect on any outcome measure.
  • The authors state that oxytocin increases the salience of social stimuli, modulates neural processing, promotes synaptic plasticity, and facilitates social learning, but its behavioural effects depend on context and can enhance trust or suspicion, affiliation or aggression, and sexual arousal or learning and memory.
  • They conclude that chronic, context-independent intranasal oxytocin should not be prescribed for children with ASD, and that oxytocin might instead prime the brain during cognitive and behavioural therapy, potentially reducing the up to 40 h of therapy per week often required.
  • Intranasal oxytocin is described as suboptimal because of its short half-life, contested blood–brain barrier penetration, and questioned intracerebral diffusion; the authors call for second-generation therapeutics that enhance endogenous oxytocin signalling or bind oxytocin receptors.

Methods

  • This is a commentary/opinion article, not a primary study; it interprets the Sikich et al. randomized, double-blind, parallel-group, placebo-controlled phase II trial and related literature.
  • The discussed trial enrolled children and adolescents with ASD aged 3–17 years, used twice-daily intranasal oxytocin at 24–40 IU or placebo for a maximum of 24 weeks, and assessed social behaviour primarily via a parent/guardian clinical questionnaire at 4-week intervals, with secondary social behavioural assessments and an IQ test.
  • The commentary’s main analysis is a narrative synthesis and argument; no new data, systematic review, or formal meta-analysis are presented.

Limitations

  • The authors state that ASD is highly heterogeneous, so chronic oxytocin could still benefit a small phenotypic subset despite being undetectable in large, diverse populations; they also note that subtler neurocognitive effects often reported preclinically were not assessed in the trial, though such effects would not be clinically meaningful without appreciable behavioural changes.
  • The authors state that intranasal oxytocin has a short half-life, contested blood–brain barrier penetration, and questioned intracerebral diffusion, likely contributing to small effect sizes in previous studies.
  • Evident from the text: as a commentary, it provides no original experimental data, and its proposals to pair oxytocin with therapy, use it before positive social experiences, or develop second-generation compounds are hypotheses rather than tested interventions.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41582-021-00602-9

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Claims the paper makes

0 of 47 cited sources checked · 0 supported · 0 flagged

  • Premisecitation

    Oxytocin does not directly cause prosocial behaviour.

    “does not directly cause prosocial behaviour”
    • Also stated in: § Abstract · plain
      “oxytocin does not directly cause prosocial behaviour in the mechanistic sense in which ACE inhibitors directly lower blood pressure.”
    Quote in the paperSubstantial claim0 of 2 sources checked
    • cites [2] Young, L. J. When too much of a good thing is bad: chronic oxytocin, development, and social impairments. Biol. Psychiatry 74, 160–161 (2013). source

      Not checked in the free run.

    • cites [6] Ford, C. L. & Young, L. J. Translational opportunities for circuit-based social neuroscience: advancing 21st century psychiatry. Curr. Opin. Neurobiol. 68, 1–8 (2021). source

      Not checked in the free run.

  • Premisecitation

    Oxytocin enhances social salience rather than social behaviour.

    “oxytocin enhances social salience rather than social behaviour”
    Quote in the paperSubstantial claim0 of 5 sources checked
    • cites [2] Young, L. J. When too much of a good thing is bad: chronic oxytocin, development, and social impairments. Biol. Psychiatry 74, 160–161 (2013). source

      Not checked in the free run.

    • cites [3] Young, L. J. Oxytocin, social cognition and psychiatry. Neuropsychopharmacology 40, 243–244 (2015). source

      Not checked in the free run.

    • cites [4] Young, L. J. & Barrett, C. E. Can oxytocin treat autism? Science 347, 825–826 (2015). source

      Not checked in the free run.

    • cites [5] Shamay-Tsoory, S. G. & Abu-Akel, A. The social salience hypothesis of oxytocin. Biol. Psychiatry 79, 194–202 (2016). source

      Not checked in the free run.

    • cites [6] Ford, C. L. & Young, L. J. Translational opportunities for circuit-based social neuroscience: advancing 21st century psychiatry. Curr. Opin. Neurobiol. 68, 1–8 (2021). source

      Not checked in the free run.

  • Premisecitation

    Oxytocin facilitates social learning.

    “oxytocin facilitates social learning”
    • Also stated in: § Abstract · plain
      “facilitates social learning by modulating neural circuits8,9”
    Quote in the paperSubstantial claim0 of 2 sources checked
    • cites [8] Froemke, R. C. & Young, L. J. Oxytocin, neural plasticity, and social behavior. Annu. Rev. Neurosci. 44, 359–381 (2021). source

      Not checked in the free run.

    • cites [9] Walum, H. & Young, L. J. The neural mechanisms and circuitry of the pair bond. Nat. Rev. Neurosci. 19, 643–654 (2018). source

      Not checked in the free run.

  • Premisecitation

    The Sikich et al. randomized controlled trial found no effect of chronic intranasal oxytocin on social behaviour or other clinical outcomes in children and adolescents with autism spectrum disorder.

    “A recent clinical trial found no effect of chronic intranasal oxytocin on social behaviour in children with autism spectrum disorders.”
    • Also stated in: § Abstract · boosted
      “A phase II clinical trial that tested the ability of intranasal oxytocin to improve social behaviour in children with autism spectrum disorders (ASD) recently made headlines for unambiguously demonstrating no clinical effect1.”
    • Also stated in: § Abstract · plain
      “However, oxytocin administration had no effect on any of the outcome measures.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [1] Sikich, L. et al. Intranasal oxytocin in children and adolescents with autism spectrum disorder. N. Engl. J. Med. 385, 1462–1473 (2021). source

      Not checked in the free run.

  • Premisecitation

    For oxytocin administration to be therapeutic and influence behaviour, it must be paired with an appropriate social context.

    “for oxytocin administration to be therapeutic and influence behaviour, it must be paired with an appropriate social context2–6”
    Quote in the paperSubstantial claim0 of 5 sources checked
    • cites [2] Young, L. J. When too much of a good thing is bad: chronic oxytocin, development, and social impairments. Biol. Psychiatry 74, 160–161 (2013). source

      Not checked in the free run.

    • cites [3] Young, L. J. Oxytocin, social cognition and psychiatry. Neuropsychopharmacology 40, 243–244 (2015). source

      Not checked in the free run.

    • cites [4] Young, L. J. & Barrett, C. E. Can oxytocin treat autism? Science 347, 825–826 (2015). source

      Not checked in the free run.

    • cites [5] Shamay-Tsoory, S. G. & Abu-Akel, A. The social salience hypothesis of oxytocin. Biol. Psychiatry 79, 194–202 (2016). source

      Not checked in the free run.

    • cites [6] Ford, C. L. & Young, L. J. Translational opportunities for circuit-based social neuroscience: advancing 21st century psychiatry. Curr. Opin. Neurobiol. 68, 1–8 (2021). source

      Not checked in the free run.

  • Classified as probably not a substantial claim. 4
  • May combine two claims. 4

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Study design and conductcitation

    The Sikich et al. trial collected data from 277 of the 290 participants enrolled across seven academic sites.

    “Data were collected from 277 of the 290 participants enrolled across seven academic sites”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [1] Sikich, L. et al. Intranasal oxytocin in children and adolescents with autism spectrum disorder. N. Engl. J. Med. 385, 1462–1473 (2021). source

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S2 (checkable), S3 (load-bearing).

    Study design and conductcitation

    The Sikich et al. study was rigorous, robust, and thorough in both design and execution.

    “the randomized, double-blind, parallel-group, placebo-controlled study by Sikich et al. was rigorous, robust, and thorough in both design and execution1”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [1] Sikich, L. et al. Intranasal oxytocin in children and adolescents with autism spectrum disorder. N. Engl. J. Med. 385, 1462–1473 (2021). source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    Oxytocin is a powerful neuromodulator that makes the brain more attentive to social stimuli, promotes synaptic plasticity, and facilitates social learning by modulating neural circuits.

    “oxytocin is a powerful neuromodulator: it makes the brain more attentive to social stimuli, promotes synaptic plasticity, and facilitates social learning by modulating neural circuits8,9”
    Quote in the paperSubstantial claim0 of 2 sources checked
    • cites [8] Froemke, R. C. & Young, L. J. Oxytocin, neural plasticity, and social behavior. Annu. Rev. Neurosci. 44, 359–381 (2021). source

      Not checked in the free run.

    • cites [9] Walum, H. & Young, L. J. The neural mechanisms and circuitry of the pair bond. Nat. Rev. Neurosci. 19, 643–654 (2018). source

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S2 (checkable).

    Interpretationreasoning

    It remains possible that chronic oxytocin could be beneficial for a small phenotypic subset of individuals despite this effect being undetectable in large, diverse populations.

    “it remains possible that chronic oxytocin could be beneficial for a small phenotypic subset of individuals despite this effect being undetectable in large, diverse populations”
    Quote in the paperNot a substantial claim
    • Rests on an assumption: ASD is highly heterogeneous.

  • May combine two claims.

    Premisecitation

    Oxytocin changes the way in which incoming social stimuli are perceived and processed, which can influence behaviour and social learning.

    “oxytocin changes the way in which incoming social stimuli are perceived and processed, which can influence behaviour and social learning in various ways8”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [8] Froemke, R. C. & Young, L. J. Oxytocin, neural plasticity, and social behavior. Annu. Rev. Neurosci. 44, 359–381 (2021). source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    Oxytocin enhances the signal-to-noise ratio of social information in brain regions that process incoming sensory signals and facilitates the flow of that information to areas involved in affective and cognitive processes, reward learning and memory.

    “The drug enhances the signal-to-noise ratio of social information in brain regions that process incoming sensory signals and facilitates the flow of that information to areas involved in affective and cognitive processes, reward learning and memory8,9”
    Quote in the paperSubstantial claim0 of 2 sources checked
    • cites [8] Froemke, R. C. & Young, L. J. Oxytocin, neural plasticity, and social behavior. Annu. Rev. Neurosci. 44, 359–381 (2021). source

      Not checked in the free run.

    • cites [9] Walum, H. & Young, L. J. The neural mechanisms and circuitry of the pair bond. Nat. Rev. Neurosci. 19, 643–654 (2018). source

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S2 (checkable), S4 (based).

    Interpretationnone given

    Subtler neurocognitive effects would not be clinically meaningful without appreciable behavioural changes.

    “such effects would not be clinically meaningful without appreciable behavioural changes”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Premisecitation

    Oxytocin increases the salience of social stimuli and fine-tunes neural processes so that an organism can better attend and respond to those stimuli.

    “Oxytocin increases the salience of social stimuli and fine-tunes neural processes so that an organism can better attend and respond to those stimuli9”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [9] Walum, H. & Young, L. J. The neural mechanisms and circuitry of the pair bond. Nat. Rev. Neurosci. 19, 643–654 (2018). source

      Not checked in the free run.

8 of 8

  • The paper relies on this without support.

    ASD is highly heterogeneous.

    “As ASD is highly heterogeneous”

  • The paper relies on this without support.

    Evidence that ASD is caused by decreased oxytocin signalling is lacking.

    “Evidence that ASD is caused by decreased oxytocin signalling is lacking”

  • The paper relies on this without support.

    Cognitive and behavioural therapies can effectively address the social deficits of ASD.

    “Cognitive and behavioural therapies can effectively address the social deficits of ASD”

  • The paper relies on this without support.

    Up to 40 hours of therapy is required per week.

    “up to 40 h of therapy is required per week”

  • The paper relies on this without support.

    The brain can more easily learn social skills through experience during sensitive periods very early in life.

    “the brain can more easily learn social skills through experience, similar to the way that language is learnt10”

  • The paper relies on this without support.

    No other clinical intervention intended to increase the signalling of a neurochemical involves administering the neurochemical itself.

    “no other clinical intervention intended to increase the signalling of a neurochemical involves administering the neurochemical itself”

  • The paper relies on this without support.

    Compounds that are administered to increase neurochemical signalling increase synthesis, synaptic release, time in synapses, or effect on receptors.

    “the compounds that are administered increase the neurochemical’s synthesis (for example, levodopa for dopamine), synaptic release (for example, amphetamines for dopamine and norepinephrine), time in synapses (for example, acetyl-cholinesterase inhibitors for acetylcholine or SSRIs for serotonin) or effect on receptors (for example, benzodiazepines and barbiturates for GABA)”

  • The paper relies on this without support.

    We also use compounds that bind directly to the target receptor.

    “We also use compounds that bind directly to the target receptor (for example, opioids)”
8 of 8

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Intranasal OXT holds some promise for treating social deficits, although it may only be beneficial in subsets of patients with low OXT levels.

    “intranasal OXT holds some promise [172, 173], although it may only be beneficial in subsets of patients with low OXT levels [174].”

    From Neural circuits regulating prosocial behaviors (2023) · cites this paper as [172]

  • Clinically, the efficacy of intranasally delivered oxytocin has been mixed, and there is a critical need for clinical trials to be designed based on our understanding of oxytocin's function in the brain, such as enhancing the salience of social stimuli.

    “Clinically, the efficacy of intranasally delivered OXT has been mixed, and there is a critical need for clinical trials to be designed based on our understanding of OXT's function in the brain, such as enhancing the salience of social stimuli (20).”

    From Oxytocin, Vasopressin, and Social Behavior: From Neural Circuits to Clinical Opportunities (2022) · cites this paper as [20]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Ford, C. L., & Young, L. J.
Affiliations
Emory University (US)
Corresponding author
Young, Larry J.
ORCID
Venue
Nature Reviews Neurology
Publisher
Springer Science and Business Media LLC
Published
2021-12-08
Volume
18
Issue
2
Pages
67-68
ISSN
  • 1759-4758 (ISSN-L)
  • 1759-4766
DOI
10.1038/s41582-021-00602-9
PMC
PMC8816821
OpenAlex
W4200237342
Semantic Scholar
136e751d24ce37f0fd31bdc74333df7f9d0d611d
Cited by
73
References
10
Citations by year
2026: 9 · 2025: 16 · 2024: 15 · 2023: 14 · 2022: 19
FWCI
11.76
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Reviews Neurology (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health (P51OD011132)
  • National Institute of Mental Health (R01MH112788, P50MH100023)
Topics
  • Social Sciences › Psychology › Social Psychology › Neuroendocrine regulation and behavior
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
Keywords
oxytocin, autism spectrum disorder, intranasal oxytocin, social behavior, social learning, prosocial behavior, behavior therapy, treatment context, clinical trial design
MeSH terms
Autism Spectrum Disorder, Autistic Disorder, Humans, Oxytocin, Social Behavior

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Claims read by deepseek-v4.1-flash under definition version 3 (extract-v3) on 2026-10-09.

Classified by jev-1.13-20260917 (gold-guideline-v0.2) on 2026-10-09.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review